Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits
Abstract
Aim: Compare medication utilization, costs and healthcare resource use in schizophrenia patients with substance-related disorders initiated on once-monthly paliperidone palmitate (PP1M) or an oral atypical antipsychotic (OAA). Materials & methods: Data from six Medicaid states (07/2009–03/2015) were used to compare outcomes between PP1M and OAA patients. Results: PP1M patients had higher 12-month antipsychotic adherence and persistence than OAA patients. PP1M patients had lower medical (mean monthly cost difference [MMCD] = US$-191, p = 0.020), higher pharmacy (MMCD = US$250, p < 0.001) and similar total costs (MMCD = US$59, p = 0.517) during the overall follow-up. PP1M patients had lower rates of outpatient visits and inpatient days but higher rates of mental health-related utilization. Conclusion: PP1M was associated with higher antipsychotic adherence and persistence, and similar total costs versus OAA.
Supplementary Material
File (supplementary data.docx)
- Download
- 29.97 KB
References
1.
Barnett JH, Werners U, Secher SM et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br. J. Psychiatry 190, 515–520 (2007).
2.
Hartz SM, Pato CN, Medeiros H et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 71(3), 248–254 (2014).
3.
Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am. J. Psychiatry 170(3), 324–333 (2013).
4.
Colizzi M, Carra E, Fraietta S et al. Substance use, medication adherence and outcome one year following a first episode of psychosis. Schizophr. Res. 170(2), 311–317 (2016).
5.
Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry 69(1), 106–113 (2008).
6.
MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla DN, Lindenmayer J-P. Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J. Manag. Care Spec. Pharm. 22(11), 1349–1361 (2016).
7.
Olivares JM, Sermon J, Hemels M, Schreiner A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann. Gen. Psychiatry 12(1), 32 (2013).
8.
Ascher-Svanum H, Zhu B, Faries DE et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 10, 2 (2010).
9.
Hjorthøj C, Østergaard MLD, Benros ME et al. Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. Lancet Psychiatry 2(9), 801–808 (2016).
10.
Winklbaur B, Ebner N, Sachs G, Thau K, Fischer G. Substance abuse in patients with schizophrenia. Dialogues Clin. Neurosci. 8(1), 37 (2006).
11.
Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J. Manag. Care Spec. Pharm. 21(9), 754–769 (2015).
12.
Haddad P, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat. Outcome Meas. 5, 43 (2014).
13.
Lafeuille M-H, Grittner AM, Fortier J et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am. J. Heal. Pharm. 72(5), 378–389 (2015).
14.
Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J. Med. Econ. 18(5), 357–365 (2014).
15.
Xiao Y, Muser E, Lafeuille M-H et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients. J. Comp. Eff. Res. 4(6), 579–592 (2015).
16.
Nasrallah HA, Gopal S, Gassmann-Mayer C et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 35(10), 2072–2082 (2010).
17.
Hargarter L, Cherubin P, Bergmans P et al. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 58, 1–7 (2015).
18.
Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br. J. Psychiatry Suppl. 52, S1–S4 (2009).
19.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. Academic Press, Inc., Toronto, Canada (1977).
20.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav. Res. 46(3), 399–424 (2011).
21.
Wobrock T, Falkai P, Schneider-Axmann T et al. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr. Res. 147(1), 132–139 (2013).
22.
Swartz MS, Wagner HR, Swanson JW et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr. Res. 100(1–3), 39–52 (2008).
23.
Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur. Neuropsychopharmacol. 25(8), 1158–1166 (2015).
24.
Koola MM, Wehring HJ, Kelly DL. The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use. J. Dual Diagn. 8(1), 50–61 (2012).
25.
Velligan DI, Weiden PJ, Sajatovic M et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J. Psychiatr. Pract. 16(5), 306–324 (2010).
26.
Portilla Fernández A, Reula L, Manrique Astiz E et al. The role of long-acting antipsychotic treatment in schizophrenia with comorbid drug use. The case of paliperidone palmitate. Eur. Psychiatry 33, S681 (2017).
27.
Green AI, Brunette MF, Dawson R et al. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J. Clin. Psychiatry 76(10), 1359–1365 (2015).
28.
Levin FR, Evans SM, Coomaraswammy S, Collins ED, Regent N, Kleber HD. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study. Am. J. Drug Alcohol Abuse. 24(3), 343–360 (1998).
29.
Soyka M, Aichmüller C, v Bardeleben U et al. Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study. Eur. Addict. Res. 9(2), 65–72 (2003).
30.
Rubio G, Martínez I, Ponce G, Jiménez-Arriero MA, López-Muñoz F, Álamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can. J. Psychiatry 51(8), 531–539 (2006).
31.
Lefebvre P, Muser E, Joshi K et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia and comorbid substance abuse. Clin Ther. 39 (7), 1380–1395 (2017).
32.
Medicaid Drug Rebate Program (2016). www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program.html
33.
Kim HM, Smith EG, Stano CM et al. Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use. BMC Health Serv. Res. 12(1), 18 (2012).
Information & Authors
Information
Published In
Copyright
© 2018 Marie-Hélène Lafeuille.
History
Published online: 15 August 2017
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits. (2017) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2017-0043
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- María Vidal-Millares, Sergio Salgado-Santamaría, Javier Vicente-Alba, Ana María Gago-Ageitos, María del Carmen García-Mahía, Indalecio Homero Carrera-Machado, Antipsicóticos de larga duración en patología dual: evolución de 5 años, Revista Colombiana de Psiquiatría, 10.1016/j.rcp.2024.04.007, 55, 1, (51-59), (2026).
- Jeffrey A. Lieberman, Alana Mendelsohn, Terry E. Goldberg, Robin Emsley, Preventing disease progression in schizophrenia: What are we waiting for, Journal of Psychiatric Research, 10.1016/j.jpsychires.2024.12.042, 181, (716-727), (2025).
- Sarah Pratt, Melanie Bennett, Mary F. Brunette, Scott Stroup, Diana O. Perkins, Lisa B. Dixon, Chapter 10. Co-occurring Disorders and Conditions, The American Psychiatric Association Publishing Textbook of Schizophrenia, Second Edition, 10.1176/appi.books.9781615379194.lg10, (205-249), (2024).
- Leslie Citrome, Mark Suett, Kelli Franzenburg, Roy Eshet, Anna Elgart, Glen Davis 3rd, Eran Harary, Orna Tohami, Marko Mychaskiw, John Kane, TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia, Neuropsychiatric Disease and Treatment, 10.2147/NDT.S459104, Volume 20, (1901-1917), (2024).
- Jacqueline Pesa, Zhiwen Liu, Alex Z. Fu, Alicia K. Campbell, Richard Grucza, Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia, Schizophrenia Research, 10.1016/j.schres.2023.09.033, 261, (170-177), (2023).
- Christoph U. Correll, Carmela Benson, Bruno Emond, Charmi Patel, Marie-Hélène Lafeuille, Dee Lin, Laura Morrison, Isabelle Ghelerter, Patrick Lefebvre, Panagiotis Mavros, Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies, Schizophrenia, 10.1038/s41537-023-00334-3, 9, 1, (2023).
- Cristiana Montemagni, Elisa Del Favero, Elena Cocuzza, Flavio Vischia, Paola Rocca, Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study, Therapeutic Advances in Psychopharmacology, 10.1177/20451253221122526, 12, (2022).
- Young-Chul Chung, Yen Kuang Yang, Ahmad Hatim Sulaiman, Paul Bergmans, Wilson Tan, Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting, Clinical Psychopharmacology and Neuroscience, 10.9758/cpn.2022.20.3.427, 20, 3, (427-439), (2022).
- Maryia Zhdanava, H Lynn Starr, Patrick Lefebvre, Todor I Totev, Aditi Shah, Kristy Sheng, Dominic Pilon, Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey, Neuropsychiatric Disease and Treatment, 10.2147/NDT.S369494, Volume 18, (1479-1493), (2022).
- Chizimuzo T.C. Okoli, Amani Kappi, Tianyi Wang, Andrew Makowski, Andrew T. Cooley, The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta‐analysis, International Journal of Mental Health Nursing, 10.1111/inm.12964, 31, 3, (469-535), (2021).